Old Web
English
Sign In
Acemap
>
authorDetail
>
I. Breitkreutz
I. Breitkreutz
University Hospital Heidelberg
Dexamethasone
Lenalidomide
Oncology
Autologous stem-cell transplantation
Hazard ratio
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma
2021
Clinical Lymphoma, Myeloma & Leukemia
Marc-A. Baertsch
Mathilde Fougereau
Thomas Hielscher
Sandra Sauer
I. Breitkreutz
Karin Jordan
Carsten Müller-Tidow
Hartmut Goldschmidt
Marc S. Raab
Jens Hillengass
Nicola Giesen
Show All
Source
Cite
Save
Citations (0)
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
2021
Cancers
Marc Andrea Baertsch
Mathilde Fougereau
Thomas Hielscher
Sandra Sauer
I. Breitkreutz
Karin Jordan
Carsten Müller-Tidow
Hartmut Goldschmidt
Marc-Steffen Raab
Jens Hillengass
Nicola Giesen
Show All
Source
Cite
Save
Citations (0)
1